Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6787)
All Articles published online
|
Publishing Process of This Article
|
Apr 21, 2014 (publication date) through Apr 15, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(15): 4208-4219 [PMID: 24764659 DOI: 10.3748/wjg.v20.i15.4208] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v20/i15/4208.htm |
| Number | Citing Articles |
| 1 |
Mattan Levi, Aron Popovtzer, Moran Tzabari, Aviram Mizrachi, Naphtali Savion, Salomon M. Stemmer, Ruth Shalgi, Irit Ben-Aharon. Cetuximab intensifies cisplatin-induced testicular toxicity. Reproductive BioMedicine Online 2016; 33(1): 102 doi: 10.1016/j.rbmo.2016.04.004
|
| 2 |
Michel B. Choueiri, John Paul Shen, Andrew M. Gross, Justin K. Huang, Trey Ideker, Paul Fanta, Anthony W.I. Lo. ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer. PLOS ONE 2015; 10(6): e0126898 doi: 10.1371/journal.pone.0126898
|
| 3 |
Daniel C. Pan, Vinu Krishnan, Alyssa K. Salinas, Jayoung Kim, Tao Sun, Sagi Ravid, Kevin Peng, Debra Wu, Md Nurunnabi, Jeffery A. Nelson, Zachary Niziolek, Junling Guo, Samir Mitragotri. Hyaluronic acid–doxorubicin nanoparticles for targeted treatment of colorectal cancer. Bioengineering & Translational Medicine 2021; 6(1) doi: 10.1002/btm2.10166
|
| 4 |
Hui Sheng, Xiaoli Wei, Qunxi Chen, Kewei Huang, Runkun Han, Yijun Liu, Wen Liu, Minjie Mao, Arumugam R. Jayakumar. The Survival Advantage of Females at Premenopausal Age Is Race Dependent in Colorectal Cancer. BioMed Research International 2020; 2020: 1 doi: 10.1155/2020/7434783
|
| 5 |
Jian‐feng Yao, Xiao‐jun Li, Li‐kun Yan, Sai He, Jian‐bao Zheng, Xiao‐rong Wang, Pei‐hua Zhou, Li Zhang, Guang‐bing Wei, Xue‐jun Sun. Role of HGF/c‐Met in the treatment of colorectal cancer with liver metastasis. Journal of Biochemical and Molecular Toxicology 2019; 33(6) doi: 10.1002/jbt.22316
|
| 6 |
Ya-Fan Yang, Gui-Ying Wang, Jing-Li He, Feng-Peng Wu, Yan-Ni Zhang. Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer. Medicine 2017; 96(12): e6335 doi: 10.1097/MD.0000000000006335
|
| 7 |
Jia-Xing Zhao, Li-Ren Liu, Xiao-Yu Yang, Fang Liu, Zhong-Guo Zhang. Serum CA19-9 as a marker of circulating tumor cells in first reflux blood of colorectal cancer patients. Oncotarget 2017; 8(40): 67918 doi: 10.18632/oncotarget.18912
|
| 8 |
Juan W Valle. BINGO: targeted therapy for advanced biliary-tract cancer. The Lancet Oncology 2014; 15(8): 778 doi: 10.1016/S1470-2045(14)70238-4
|
| 9 |
Giulia Fornasier, Sara Francescon, Paolo Baldo. An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review. Advances in Therapy 2018; 35(10): 1497 doi: 10.1007/s12325-018-0791-0
|
| 10 |
Poojarani Panda, Henu Kumar Verma, Lakkakula V. K. S. Bhaskar. Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies. Onco 2023; 3(3): 127 doi: 10.3390/onco3030010
|
| 11 |
Feng Xiong, Yu-Wen Zhou, Ya-Ting Hao, Gui-Xia Wei, Xiao-Rong Chen, Meng Qiu. Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC). Expert Review of Gastroenterology & Hepatology 2023; : 1 doi: 10.1080/17474124.2023.2232718
|
| 12 |
Soudabeh Kavousipour, Fathemeh Khademi, Mozhdeh Zamani, Bahareh Vakili, Pooneh Mokarram. Novel biotechnology approaches in colorectal cancer diagnosis and therapy. Biotechnology Letters 2017; 39(6): 785 doi: 10.1007/s10529-017-2303-8
|
| 13 |
Louisa Lo, Dainik Patel, Amanda R Townsend, Timothy J Price. Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. Expert Opinion on Drug Metabolism & Toxicology 2015; 11(12): 1907 doi: 10.1517/17425255.2015.1112787
|
| 14 |
Ali Razaghi, Kirsten Heimann, Patrick M. Schaeffer, Spencer B. Gibson. Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies. Apoptosis 2018; 23(2): 93 doi: 10.1007/s10495-018-1440-4
|
| 15 |
Yue Wu, Haowei Jia, Xinqi Bao, Tianyu Zhu, Ruixin Li, Hongchao Zhao, Junfeng Sun. Gastrointestinal Disasters of Cetuximab in the Treatment of Metastatic Colorectal Cancer: Mechanism and its Effect on Prognosis. Aging Pathobiology and Therapeutics 2020; 2(2): 64 doi: 10.31491/APT.2020.06.016
|
| 16 |
Sirichat Kaowinn, Seung Won Jun, Chang Seok Kim, Dong-Myeong Shin, Yoon-Hwae Hwang, Kyujung Kim, Bosung Shin, Chutima Kaewpiboon, Hyeon Hee Jeong, Sang Seok Koh, Oliver H. Krämer, Randal N. Johnston, Young-Hwa Chung. Increased EGFR expression induced by a novel oncogene, CUG2, confers resistance to doxorubicin through Stat1-HDAC4 signaling. Cellular Oncology 2017; 40(6): 549 doi: 10.1007/s13402-017-0343-7
|
| 17 |
Nele Boeckx, Ken Op de Beeck, Vanessa Deschoolmeester, Guy Van Camp, Patrick Pauwels, Marc Peeters. Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives. Current Colorectal Cancer Reports 2014; 10(4): 380 doi: 10.1007/s11888-014-0242-5
|
| 18 |
Daniel-Clement Osei-Bordom, Sivesh Kamarajah, Niki Christou. Colorectal Cancer, Liver Metastases and Biotherapies. Biomedicines 2021; 9(8): 894 doi: 10.3390/biomedicines9080894
|
| 19 |
Zhexuan Lin, Quanwei Zhang, Wenhong Luo. Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions. European Journal of Pharmacology 2016; 793: 76 doi: 10.1016/j.ejphar.2016.10.039
|
| 20 |
Anggraeni E. Kusumaningrum, Sarce Makaba, Eyhab Ali, Mandeep Singh, Mohammed N. Fenjan, Irodakhon Rasulova, Neeti Misra, Sada G. Al‐ Musawi, Ali Alsalamy. A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance. Cell Biochemistry and Function 2024; 42(1) doi: 10.1002/cbf.3906
|
| 21 |
Marc Peeters, Kelly S. Oliner, Timothy J. Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew H. Strickland, Gregory Wilson, Tudor E. Ciuleanu, Laslo Roman, Eric Van Cutsem, Pei He, Hua Yu, Reija Koukakis, Jan-Henrik Terwey, Andre S. Jung, Roger Sidhu, Scott D. Patterson. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clinical Cancer Research 2015; 21(24): 5469 doi: 10.1158/1078-0432.CCR-15-0526
|
| 22 |
Long Bai, Feng Wang, Zhe-zhen Li, Chao Ren, Dong-sheng Zhang, Qi Zhao, Yun-xin Lu, De-shen Wang, Huai-qiang Ju, Miao-zhen Qiu, Zhi-qiang Wang, Feng-hua Wang, Rui-hua Xu. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer. Medicine 2016; 95(51): e4531 doi: 10.1097/MD.0000000000004531
|